Advanced Cancer Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (End Use, Test), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

End Use Segment Analysis: Hospitals & Cancer Specialty Centers (Largest Segment) vs Diagnostic Laboratories (Independent & Reference Labs) (Fastest-Growing Segment)

The hospitals & cancer specialty centers segment accounted for the largest share of 47.71% in the 2026 advanced cancer diagnostics market, driven by their central role in comprehensive cancer diagnosis, treatment planning, and multidisciplinary patient management. These healthcare settings offer access to sophisticated diagnostic infrastructure, specialized oncology expertise, and integrated clinical services, allowing advanced diagnostic tests to be incorporated directly into patient care pathways. The availability of imaging systems, molecular testing, pathology services, and specialist consultations within or through affiliated facilities supports efficient diagnostic evaluation and treatment decision-making. Increasing cancer incidence and the growing emphasis on early and precise disease detection are further strengthening demand for advanced diagnostics in hospitals and specialized cancer centers. In addition, the increasing use of personalized treatment approaches requires detailed molecular and clinical information, encouraging healthcare providers to expand their diagnostic capabilities and integrate advanced testing into routine oncology workflows.

The diagnostic laboratories, including independent and reference labs, segment is expected to grow at the fastest pace during the forecast period, supported by increasing outsourcing of specialized diagnostic testing and the expanding complexity of advanced cancer diagnostics. Independent and reference laboratories can provide specialized testing capabilities, advanced laboratory infrastructure, and access to skilled technical expertise that may not be available across all healthcare facilities. Their ability to process complex molecular, genetic, and biomarker-based tests enables hospitals and physicians to access specialized diagnostic services without developing all capabilities internally. Growing demand for precision oncology is also increasing the need for highly specialized laboratory testing, while improvements in laboratory automation and digital connectivity are facilitating efficient exchange of diagnostic information. As healthcare systems seek cost-effective access to advanced testing and increasingly rely on specialized diagnostic networks, independent and reference laboratories are expected to gain a larger role in cancer diagnostics.

Test Segment Analysis: Imaging-Based Diagnostics (Largest Segment) vs Liquid Biopsy (Fastest-Growing Segment)

The imaging-based diagnostics segment accounted for the largest share of 28.91% in the 2026 advanced cancer diagnostics market, supported by the established role of medical imaging in cancer detection, tumor characterization, staging, treatment planning, and disease monitoring. Imaging modalities provide clinicians with non-invasive methods to visualize tumors and assess their location, size, and progression, making them fundamental to cancer management across multiple disease types. Continuous improvements in imaging quality, image processing, and diagnostic interpretation are enhancing the ability to identify abnormalities and support more precise clinical decisions. Imaging-based diagnostics are also widely integrated into hospital and oncology workflows, allowing diagnostic findings to be combined with other clinical and laboratory information. The established infrastructure, broad clinical applicability, and continuing technological advancements in cancer imaging are expected to sustain the segment's leading position.

The liquid biopsy segment is expected to grow at the fastest pace during the forecast period, driven by increasing demand for minimally invasive approaches to cancer detection, molecular profiling, and disease monitoring. Liquid biopsy can analyze cancer-related biomarkers from biological fluids, offering opportunities to obtain molecular information without relying exclusively on invasive tissue sampling. Its potential applications in early detection, treatment selection, monitoring of treatment response, and identification of emerging disease characteristics are increasing interest among clinicians and researchers. The ability to support repeated testing can also make liquid biopsy valuable for monitoring changes in a patient's disease profile over time. As precision oncology continues to emphasize individualized treatment decisions and real-time assessment of tumor characteristics, advances in biomarker detection, molecular analysis, and assay sensitivity are expected to accelerate adoption of liquid biopsy technologies.